AbbVie Inc (NYSE:ABBV) and Xilio Therapeutics, Inc. (NASDAQ:XLO) announced a collaboration and option-to-license agreement to ...

Xilio Therapeutics (XLO) announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane ...

Neonates and young infants exposed to extracorporeal circulation during extracorporeal membrane oxygenation ... to investigate the hypothesis that epithelial apoptosis is an early event that ...

Xilio Therapeutics Inc. has announced three wholly owned preclinical programs for masked T-cell engagers targeting prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2) and ...